Please use this identifier to cite or link to this item:
Title: Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin
Authors: Zalesak, M.
Siu, K.
Francis, K.
Yu, C.
Alvrtsyan, H.
Rao, Y.
Walker, D.
Sander, S.
Miyasato, G.
Matchar, D. 
Sanchez, H.
Keywords: Anticoagulants
Atrial fibrillation
Issue Date: Sep-2013
Citation: Zalesak, M., Siu, K., Francis, K., Yu, C., Alvrtsyan, H., Rao, Y., Walker, D., Sander, S., Miyasato, G., Matchar, D., Sanchez, H. (2013-09). Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circulation: Cardiovascular Quality and Outcomes 6 (5) : 567-574. ScholarBank@NUS Repository.
Abstract: Background-Oral anticoagulation therapy is the primary tool in reducing stroke risk in patients with nonvalvular atrial fibrillation but is underused. Patients nonpersistent with therapy contribute to this underuse. The objective of this study was to compare persistence rates in newly diagnosed nonvalvular atrial fibrillation patients treated with warfarin versus dabigatran as their oral anticoagulation. Methods and Results-US Department of Defense administrative claims were used to identify patients receiving warfarin or dabigatran between October 28, 2010, and June 30, 2012. Patient records were examined for a minimum of 12 months before index date to restrict the analyses to those newly diagnosed with nonvalvular atrial fibrillation and naive-to-treatment, identifying 1775 on warfarin and 3370 on dabigatran. Propensity score matching was used to identify 1745 matched pairs. Persistence was defined as time on therapy to discontinuation. Kaplan-Meier curves were used to depict persistence over time. Cox proportional hazards model was used to determine the factors significantly associated with persistence. Using a 60-day permissible medication gap, the persistence rates were higher for dabigatran than for warfarin at both 6 months (72% versus 53%) and 1 year (63% versus 39%). Patients on dabigatran with a low-to-moderate risk of stroke (CHADS 23) had a higher likelihood of nonpersistence (hazard ratios, 1.37; 95% confidence interval, 1.17-1.60; P
Source Title: Circulation: Cardiovascular Quality and Outcomes
ISSN: 19417713
DOI: 10.1161/CIRCOUTCOMES.113.000192
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Nov 30, 2022


checked on Nov 30, 2022

Page view(s)

checked on Nov 24, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.